. Average proportions of NLS in contemporary African (AF, black), Asian (AS, dark gray) and European (EU, light gray) populations calculated based on sequence data from the 1000 genomes project 13 .
. Robustness estimates for the average proportions of NLS located within genes annotated in the LCP term in contemporary African, European and Asian populations.
The boxes show quartiles and the median of the data, the whiskers extend to the minimum and maximum data values located within 0.5 interquartile range from the box. The variance shown by the boxplots was calculated by bootstrapping genomic sites (n=498) 1,000 times. Black squares represent the number of sites with the positive selection signal, measured as a CMS score higher or equal to a CMS score threshold of 2 (A), 1 (B) or 0.5 (C-E) in the LCP gene regions in human populations of European (EU), Asian (AS) and African (AF) descent. For each population, the numbers of sites in the LCP term were normalized to the numbers of sites passing the same CMS score threshold in the same number of gene regions sampled within the same population among all annotated genes (A-C), among all protein-coding genes (D), and among protein-coding genes directly linked with non-LCP metabolic pathways according to KEGG annotation (E). The boxplots represent variation of normalized site number estimates obtained by bootstrapping LCP gene regions 1,000 times. The boxes show quartiles and the median of the data, the whiskers extend to the minimum and maximum data values located within 0.5 interquartile range from the box. The numbers above the boxplots show the proportion of the normalized site numbers in Europeans (EU), observed in 1,000 bootstraps over LCP gene regions (n=38), that were less or equal to the normalized site numbers in Africans (AF) or Asians (AS). Figure 4 . Positive selection signal measured using CMS scores for genes within the LCP term in contemporary humans of European decent.
Supplementary
On the right, difference of CMS scores in Europeans to CMS scores in Asians for LCP genes (n=45) containing excess of NLS in Europeans compared to Asians (EU>AS). On the left, difference of CMS scores in Europeans to CMS scores in Asians for LCP genes (n=20) containing fewer NLS in Europeans compared to Asians (EU<AS). The boxes show quartiles and the median of the data, the whiskers extend to the minimum and maximum data values located within 0.5 interquartile range from the box. Figure 5 . Metabolite concentration divergence between chimpanzees and three human populations in the LCP term and other metabolic pathways, and controlled for differences in sex, age, postmortem delay and tissue preservation based on RNA integrity estimates (RIN values) among species and populations.
The boxplots show the distribution of divergence estimates measured between chimpanzees and humans of African (AF), Asian (AS) and European (EU) descent for seven metabolic categories directly linked to LCP genes (red) and metabolites in other metabolic pathways (gray). The boxes show quartiles and the median of the data, the whiskers extend to the minimum and maximum data values located within 0.5 interquartile range from the box. The variance shown by the boxplots was calculated by bootstrapping mass-spectrometry peaks (n=1,090 for LCP and n=163 for other metabolite categories) 1,000 times. To minimize the influence of environmental differences among populations, metabolic divergence in the LCP term was normalized to the divergence based on all other metabolic pathways within the same population. The numbers above the red boxplots show the proportion of values from the LCP divergence distribution that were smaller than, or equal to, the divergence values calculated based on other metabolic pathways shown by the gray boxplots. The distributions shown are based on residuals of the linear regression models used to exclude possible linear effects of differences in (A) sex, (B) age, (C) postmortem delay and (D) tissue preservation based on RNA integrity estimates (RIN values) among species and populations. Figure 6 . Lipid concentration and gene expression divergence in LCP and two other metabolic pathways: KEGG sphingolipid metabolism (KSM) and KEGG glycerolipid metabolism (KGM).
(A) and (B) Lipid concentration divergence in LCP relative to KSM (A) or KGM (B) pathways in three human populations. The boxplots show the distribution of divergence estimates measured between chimpanzees and humans of African (AF), Asian (AS) and European (EU) descent for seven metabolic categories directly linked to LCP genes (red), as well as for five metabolic categories in KSM pathway or for five metabolic categories in KGM pathway (gray). (C) and (D) Gene expression divergence in LCP relative to KSM (C) or KGM (D) pathways in three human populations. The boxplots show the distribution of divergence estimates measured between chimpanzees and humans of AF, AS and EU descent for LCP genes directly linked to the seven metabolic categories (red), as well as for KSM or KGM genes directly linked to corresponding metabolites (gray). The boxes show quartiles and the median of the data, the whiskers extend to the minimum and maximum data values located within 0.5 interquartile range from the box. The variance shown by the boxplots was calculated by bootstrapping massspectrometry peaks (n=1,090 for LCP, n=154 for KSM, and n=474 for KGM) and RPKM values (n=6 for LCP, n=24 for KSM, and n=12 for KGM) 1,000 times. To minimize the influence of environmental differences among populations, metabolic/gene expression divergence in the LCP term was normalized to the divergence of KSM or KGM pathways within the same population. The numbers above the red boxplots show the proportion of values from the LCP divergence distribution that were smaller than, or equal to, the divergence values calculated based on KSM or KGM pathways shown by the gray boxplots. Figure 7 . Gene expression divergence between chimpanzees and three human populations in the LCP term and other genes expressed in the prefrontal cortex, controlled for differences in sex, age, postmortem delay and tissue preservation based on RNA integrity estimates (RIN values) among species and populations.
The boxplots show the distribution of divergence estimates measured between chimpanzees and humans of African (AF), Asian (AS) and European (EU) descent for LCP genes directly linked to seven LCP metabolic categories (red) and other LCP genes (gray). The boxes show quartiles and the median of the data, the whiskers extend to the minimum and maximum data values located within 0.5 interquartile range from the box. The variance shown by the boxplots was calculated by bootstrapping RPKM values (n=6 for LCP/metabo and n=26 for LCP/others) 1,000 times. To minimize the influence of environmental differences among populations, gene expression divergence in the LCP term was normalized to the divergence based on all other metabolic pathways within the same population. The numbers above the red boxplots show the proportion of values from the LCP divergence distribution that were smaller than, or equal to, the divergence values calculated based on other metabolic pathways shown by the gray boxplots. Figure 8 . Distances between NLS located within six LCP genes connected to European-specific metabolic changes and transcription start sites (TSS) of these genes.
On the right, distances to TSS for the polymorphic sites with higher D-score in Europeans compared to Asians and Africans (EU>A, n=14), representing European NLS. On the left, distances to TSS for the polymorphic sites with lower D-score in Europeans compared to Asians and Africans (EU<A, n=27), representing non-European (Asian) NLS. The boxes show quartiles and the median of the data, the whiskers extend to the minimum and maximum data values located within 0.5 interquartile range from the box. The left panel represents the proportions of sites in genes annotated in the LCP term. The right panel represents the genome average. The proportions are shown for the genomic sites with substitution types potentially caused by DNA damage characteristic of ancient DNA samples (C/T + A/G), for genomic sites containing all other substitution types (Others), and for the total of all genomic sites with a sequence difference between the chimpanzee and the Neanderthal genomes (Total). Proportions were calculated using the Altai and Vindjia Neanderthal genomes separately, or using the consensus genome built using both Neanderthal genomes (Combined). The proportions are shown for LCP genes and for the entire genome: the total of all genomic sites with a sequence difference between the chimpanzee and the Neanderthal genomes. Supplementary Table 10 . Genes within the LCP term detected in the RNA-seq data that are directly linked to the seven metabolic categories within the LCP pathway.

Gene name Linked metabolites * Gene function ** CEL C00422, C02530
GO:0006629 lipid metabolic process; GO:0006641 triglyceride metabolic process; GO:0006707 cholesterol catabolic process; GO:0009062 fatty acid catabolic process; GO:0018350 protein esterification; GO:0030157 pancreatic juice secretion; GO:0030299 intestinal cholesterol absorption; GO:0044241 lipid digestion; GO:0044258 intestinal lipid catabolic process; GO:0044281 small molecule metabolic process; GO:0046514 ceramide catabolic process PLA2G15 C04230
GO:0006672 ceramide metabolic process; GO:0009062 fatty acid catabolic process; GO:0046470 phosphatidylcholine metabolic process; GO:0006629 lipid metabolic process PLA2G4B C00350, C04230, C00157
GO:0006644 phospholipid metabolic process; GO:0006654 phosphatidic acid biosynthetic process; GO:0006954 inflammatory response; GO:0006987 activation of signaling protein activity involved in unfolded protein response; GO:0007567 parturition; GO:0019369 arachidonic acid metabolic process; GO:0019722 calciummediated signaling; GO:0030968 endoplasmic reticulum unfolded protein response; GO:0036148 phosphatidylglycerol acyl-chain remodeling; GO:0036150 phosphatidylserine acyl-chain remodeling; GO:0036151 phosphatidylcholine acylchain remodeling; GO:0036152 phosphatidylethanolamine acyl-chain remodeling; GO:0044267 cellular protein metabolic process; GO:0044281 small molecule metabolic process; GO:0046474 glycerophospholipid biosynthetic process; GO:0046475 glycerophospholipid catabolic process PLA2G4C C00350, C04230, C00157
GO:0006644 phospholipid metabolic process; GO:0006954: inflammatory response; GO:0007567 parturition; GO:0019369 arachidonic acid metabolic process; GO:0035556 intracellular signal transduction; GO:0036149 phosphatidylinositol acylchain remodeling; GO:0036151 phosphatidylcholine acyl-chain remodeling; GO:0036152 phosphatidylethanolamine acyl-chain remodeling; GO:0044281 small molecule metabolic process; GO:0046474 glycerophospholipid biosynthetic process; GO:0046475 glycerophospholipid catabolic process PNPLA3 C00422
GO:0036155 acylglycerol acyl-chain remodeling; GO:0046474 glycerophospholipid biosynthetic process; GO:0006644 phospholipid metabolic process; GO:0044281 small molecule metabolic process; GO:0019432 triglyceride biosynthetic process; GO:0019433 triglyceride catabolic process SMPD3 C00195, C00550
GO:0007049 cell cycle; GO:0006687 glycosphingolipid metabolic process; GO:0007275 multicellular organismal development; GO:0030072 peptide hormone secretion; GO:0044281 small molecule metabolic process; GO:0006685 sphingomyelin catabolic process * KEGG accession numbers of the linked metabolic categories. ** Gene function according to Gene Ontology annotation 20 Fisher's exact test p-values, fold enrichments, Benjamini-corrected Fisher's exact test p-values and FDR were estimated using DAVID functional annotation tool 33 with default parameters.
Only diseases with p-values lower than 0.05 are listed.
